- Home
- KUKE vs DXR Comparison
KUKE vs DXR Comparison
Compare KUKE & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- DXR
- Stock Information
- Founded
- KUKE 2002
- DXR 1970
- Country
- KUKE China
- DXR United States
- Employees
- KUKE N/A
- DXR N/A
- Industry
- KUKE Other Consumer Services
- DXR Medical/Dental Instruments
- Sector
- KUKE Real Estate
- DXR Health Care
- Exchange
- KUKE Nasdaq
- DXR Nasdaq
- Market Cap
- KUKE 42.0M
- DXR 46.9M
- IPO Year
- KUKE 2021
- DXR N/A
- Fundamental
- Price
- KUKE $0.59
- DXR $13.50
- Analyst Decision
- KUKE
- DXR Strong Buy
- Analyst Count
- KUKE 0
- DXR 1
- Target Price
- KUKE N/A
- DXR $25.00
- AVG Volume (30 Days)
- KUKE 920.8K
- DXR 5.1K
- Earning Date
- KUKE 10-21-2025
- DXR 01-01-0001
- Dividend Yield
- KUKE N/A
- DXR N/A
- EPS Growth
- KUKE N/A
- DXR 3.46
- EPS
- KUKE N/A
- DXR 0.36
- Revenue
- KUKE $9,442,397.00
- DXR $66,306.00
- Revenue This Year
- KUKE N/A
- DXR N/A
- Revenue Next Year
- KUKE N/A
- DXR N/A
- P/E Ratio
- KUKE N/A
- DXR $38.30
- Revenue Growth
- KUKE N/A
- DXR N/A
- 52 Week Low
- KUKE $0.52
- DXR $6.55
- 52 Week High
- KUKE $10.00
- DXR $14.00
- Technical
- Relative Strength Index (RSI)
- KUKE 19.47
- DXR 66.65
- Support Level
- KUKE $0.55
- DXR $13.39
- Resistance Level
- KUKE $0.62
- DXR $14.00
- Average True Range (ATR)
- KUKE 0.09
- DXR 0.50
- MACD
- KUKE -0.04
- DXR 0.13
- Stochastic Oscillator
- KUKE 5.88
- DXR 80.93
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.